Proactive Investors - Run By Investors For Investors

Imugene appoints venture capital executive to board

The company finished the March quarter with $21 million in the bank.
three empty board seats
It is it well-positioned to progress its commercial and clinical milestones

Imugene Ltd (ASX:IMU) has appointed Dr Jens Eckstein as a non-executive director to its board effective as of today.

Dr Eckstein is a leading biotechnology executive and managing partner of Apollo Ventures, a venture capital firm that invests in seed and early stage biotechnology companies.

He has more than 15 years venture capital experience funding early to clinical stage biopharmaceutical companies.

READ: Imugene to present new data from HER-Vaxx cancer vaccine phase 1b trial

Imugene’s executive chairman Paul Hopper said: “Imugene continues to attract a world class team.

“We welcome Dr Eckstein to the board and look forward to working together to advance our highly promising cancer immuno therapy pipeline.”

Strong pipeline of cancer vaccines in development

The company has a strong pipeline of cancer vaccines in development.

View full IMU profile View Profile

Imugene Ltd Timeline

Related Articles

antibodies
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences
technician's in a lab clean-room
March 12 2019
The Maryland company is seeing revenue surge through an expansion of contract manufacturing services, particularly in the area of CAR T-cell therapies
doctor
June 11 2019
Oncimmune is a specialist in the field of immunodiagnostics

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use